A Phase I-II Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma.

Trial Profile

A Phase I-II Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Glioma; Paraganglioma; Pheochromocytoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Molecular Insight Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2009 Planned end date changed from 1 Apr 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Trial phase changed from I to I/II as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top